A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA
Authors:
- 5 February 2024
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 59 (4) , 315-328
Abstract
Background Currently, standard treatments for chronic hepatitis B such as nucleos(t)ide analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a functional cure (defined as sustained HBsAg loss). We report the discovery of a novel, 4-pyridone compound, SAG-524, a potent and orally bioavailable small molecule inhibitor of HBV replication. Methods The antiviral characteristics and selectivity of SAG-524 and its derivative compound against HBV were evaluated in HBV-infection assays and HBV-infected chimeric urokinase-type plasminogen activator/severe combined immunodeficiency mice with humanized livers (PXB mice), alone or in combination with entecavir. Toxicity studies were conducted in mice and monkeys. Results SAG-524 reduced HBV-DNA (IC50 = 0.92 nM) and HBsAg (IC50 = 1.4 nM) in the supernatant of the HepG2.2.15 cells. SAG-524 selectively destabilized HBV-RNA via PAPD5, but not GAPDH or albumin mRNA, by shortening the poly(A) tail. PAPD5 may also be involved in HBV regulation via ELAVL1. In a study of HBV-infected PXB mice, SAG-524 produced potent reductions of serum HBsAg and HBcrAg, and the minimum effective dose was estimated to be 6 mg/kg/day. The combination therapy with entecavir greatly reduced HBsAg and cccDNA in the liver due to reduction of human hepatocytes with good tolerability. Administration of SAG-524 to monkeys, up to 1000 mg/kg/day for two weeks, led to no significant toxicity, as determined by blood tests and pathological images. Conclusions We have identified SAG-524 as novel and orally bioavailable HBV-RNA destabilizers which can reduce HBsAg and HBV-DNA levels, and possibly contribute a functional cure. Graphical AbstractKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP23fk0310518)
This publication has 46 references indexed in Scilit:
- CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated ExhaustionPLOS Pathogens, 2013
- Higher-Order Chromatin Regulation and Differential Gene Expression in the Human Tumor Necrosis Factor/Lymphotoxin Locus in Hepatocellular Carcinoma CellsMolecular and Cellular Biology, 2012
- Natural history of chronic hepatitis B REVEALedJournal of Gastroenterology and Hepatology, 2011
- Pathogenesis of hepatitis B virus infectionPathologie Biologie, 2010
- How chronic viral infections impact on antigen‐specific T‐cell responsesEuropean Journal of Immunology, 2010
- Benefits and risks of interferon therapy for hepatitis B #Hepatology, 2009
- Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens†‡Hepatology, 2006
- mRNA Openers and Closers: Modulating AU‐Rich Element‐Controlled mRNA Stability by a Molecular Switch in mRNA Secondary StructureChemBioChem, 2004
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Serum Hbv Dna As A Marker of Efficacy During Therapy for Chronic Hbv Infection: Analysis and Review of the LiteratureHepatology, 2003